Using Modified Antigenic Sequences to Develop Cancer Vaccines: Are We Losing the Focus?
Open Access
- 30 November 2004
- journal article
- perspective
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 1 (2) , e26
- https://doi.org/10.1371/journal.pmed.0010026
Abstract
Are short synthetic peptides the key to developing cancer vaccines? And what are the obstacles in the way?Keywords
This publication has 12 references indexed in Scilit:
- Diversity and Recognition Efficiency of T Cell Responses to CancerPLoS Medicine, 2004
- Cancer vaccines based on dendritic cells loaded with tumor-associated antigensCell Biology and Toxicology, 2001
- Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated KillingMolecular Medicine, 2000
- Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral DeterminantsThe Journal of Experimental Medicine, 1999
- Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.1998
- Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.1996
- Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.The Journal of Immunology, 1996
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Cytotoxic T cells recognize fragments of the influenza nucleoproteinCell, 1985
- T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes.The Journal of Experimental Medicine, 1979